… in DCs encountering differential proteasome inhibition displayed no … deubiquitinase inhibitor
b-AP15 in contrast to bortezomib. … that the proteasome inhibitor bortezomib influences DC …

… -κB inhibitor, pentoxifylline (PTX), or the proteasome inhibitor, bortezomib (BTZ), can re-sensitize
breast cancer cells to … The differential basal NF-κB activity in MCF-7 and MDA-MB-231 …

… breast cancer cells when compared to HER2-negative cells. In … In a different study, the
proteasome inhibitor bortezomib and … Similarly, no differential action on DOX pharmacokinetics …

… While treatment with the proteasome inhibitor bortezomib substantially … FLII has been
recently reported to promote breast cancer … RNA-seq differential gene expression analysis was …

… cancer eligible for the phase 2 study (differentiated thyroid … The bortezomib-induced
enhancement of doxorubicin effect … a suppressive effect on bortezomib-induced cytotoxic effect …

… and Btz synergistically kill breast cancer cells by inducing … the resistance of cancer cells to
proteasome inhibitors (PIs), we … and Ca 2+ modulation may contribute to the differential effect …

… proteasome inhibitor bortezomib. Overall, our in vitro study demonstrates that NFV can
therapeutically target HGSOC cells of differential … inhibition of HER2-positive breast cancer cells …

… breast cell lines (three cancerous, and one non-cancerous) exposed to MitoQ and MitoApo.
Similar to previous reports 21,22,23 , Bortezomib, a proteasome inhibitor, … by the differential …

… example, bortezomib results in neurotoxicity in differentiated … of bortezomib has shown
that proteasome inhibitors are … In breast cancer cells, treatment with paclitaxel and MG132 …

… Differential gene expression was evaluated using DESeq2 (version 1.28.1, RRID:… a panel
of proteasome inhibitors approved by the FDA for blood cancer therapy: bortezomib, ixazomib, …